Abstract
1 EEGs were recorded from patients with depressive illness before and after four weeks of treatment with mianserin, maprotiline or placebo.
2 Visual analysis of the records showed a small but statistically significant increase in frequency of beta activity in the mianserin group.
3 One subject taking maprotiline developed spike and wave discharges but had no convulsive seizures.
4 The findings do not support those of previous studies. It seems that changes seen in the EEG early after treatment are not sustained for four weeks.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Edwards J. G., Glen-Bott M. Mianserin and convulsive seizures. Br J Clin Pharmacol. 1983;15 (Suppl 2):299S–311S. doi: 10.1111/j.1365-2125.1983.tb05879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edwards J. G., Goldie A. Placebo-controlled trial of mianserin and maprotiline in primary depressive illness: a preliminary report. Br J Clin Pharmacol. 1983;15 (Suppl 2):239S–248S. doi: 10.1111/j.1365-2125.1983.tb05871.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fink M., Irwin P., Gastpar M., DeRidder J. J. EEG, blood level, and behavioral effects of the antidepressant mianserin (ORG GB-94). Psychopharmacology (Berl) 1977 Nov 15;54(3):249–254. doi: 10.1007/BF00426572. [DOI] [PubMed] [Google Scholar]
- Irwin P., Fink M. Electroencephalogram study of mianserin in depressed patients. Br J Clin Pharmacol. 1978;5 (Suppl 1):43S–47S. [PMC free article] [PubMed] [Google Scholar]
- Itil T. M., Polvan N., Hsu W. Clinical and EEG effects of GB-94, a "tetracyclic" antidepressant (EEG model in discovery of a new psychotropic drug). Curr Ther Res Clin Exp. 1972 Jul;14(7):395–413. [PubMed] [Google Scholar]
- Jovanović U. J., Tan-Eli B. The effect of compound CIBA 34,276-Ba on the cortical electro-encephalogram of healthy persons. Eur Neurol. 1970;4(1):39–56. doi: 10.1159/000114008. [DOI] [PubMed] [Google Scholar]
- Kugler J., Lorenzi E., Spatz R., Zimmermann H. Drug-induced paroxysmal EEG-activities. Pharmakopsychiatr Neuropsychopharmakol. 1979 Mar;12(2):165–172. doi: 10.1055/s-0028-1094607. [DOI] [PubMed] [Google Scholar]
- Lempérièr T., Féline A., Adès J., Pilate C., Gutmann A. Considérations sur l'utilisation du Ludiomil en perfusions intra-veineuses dans le traitment des états dépressifs. Ann Med Psychol (Paris) 1975 Nov;2(4):748–756. [PubMed] [Google Scholar]
- Logue J. N., Sachais B. A., Feighner J. P. Comparisons of maprotiline with imipramine in severe depression: a multicenter controlled trial. J Clin Pharmacol. 1979 Jan;19(1):64–74. doi: 10.1002/j.1552-4604.1979.tb01618.x. [DOI] [PubMed] [Google Scholar]
- Misurec J., Náhunek K., Rodová A. EEG changes in treatment with maprotiline. Act Nerv Super (Praha) 1973 May;15(2):110–110. [PubMed] [Google Scholar]
- Riess W. The double radio-isotope derivative technique for the assay of drugs in biological material. I. The determination of maprotiline. Anal Chim Acta. 1974 Feb;68(2):363–376. doi: 10.1016/s0003-2670(01)82591-5. [DOI] [PubMed] [Google Scholar]
- Singh A. N., Saxena B., Gent M., Nelson H. L. Maprotiline (Ludiomil, Ciba 34,276-BA) and imipramine in depressed outpatients: a double-blind clinical study. Curr Ther Res Clin Exp. 1976 Apr;19(4):451–462. [PubMed] [Google Scholar]
- Zivin L., Marsan C. A. Incidence and prognostic significance of "epileptiform" activity in the eeg of non-epileptic subjects. Brain. 1968;91(4):751–778. doi: 10.1093/brain/91.4.751. [DOI] [PubMed] [Google Scholar]